Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HERC2 pseudogene 2 (HERC2P2)
- Target
- HERC2P2
- Molecular classification
- Other (Pseudogene, non-coding RNA)
01
Overview
HERC2 pseudogene 2 (HERC2P2, also known as D15F37S3) is a non-coding RNA transcribed from a pseudogene homologous to HERC2, which encodes a HECT-type E3 ubiquitin ligase. HERC2P2 does not produce a functional protein but may regulate gene expression post-transcriptionally, possibly via a competing endogenous RNA (ceRNA) mechanism that affects RNA splicing and modulates the expression of genes involved in cell cycle, proliferation, and tumor progression. HERC2P2 is found to be differentially expressed in various cancers, with upregulation or downregulation correlating to prognosis or disease subtype. It has potential utility as a biomarker in cancer due to its association with clinical outcomes, reflecting the ongoing interest in non-coding RNAs as modulators of disease biology. No drugs are known to interact directly with HERC2P2, and it is not a direct therapeutic target.
- Other names
- D15F37S3HERC2P2HERC2 pseudogene 2
02
Mechanism of action
Not applicable, as no drugs target HERC2P2 directly.
03
Biological functions
Regulation of gene expression (as a long non-coding RNA, lncRNA)Competing endogenous RNA (ceRNA) function, potentially influencing RNA splicingMay act as a tumor suppressor in some cancers (indirectly, via RNA expression modulation)
04
Disease associations
Cancer (associated with tumor suppression or progression, depending on context)Prognostic marker in head and neck squamous cell carcinoma (HNSCC)Reported downregulation in vocal cord leukoplakia and high-grade gliomas; overexpression inhibits glioma proliferationDownregulated in breast cancer and suggested as a potential blood-based biomarker
05
Safety considerations
Not directly applicable. Being a pseudogene and non-coding RNA, there are no described therapeutic safety concerns.
06
Biomarkers
Expression level of HERC2P2 RNA may be a biomarker for prognosis in certain cancers (e.g., HNSCC, glioma, breast cancer)
Beyond the preview
Go deeper on HERC2 pseudogene 2 (HERC2P2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HERC2 pseudogene 2 (HERC2P2).